α-1 抗胰蛋白酶缺乏

American Thoracic Society/European Respiratory Society Statement. Standards for the diagnosis and management of individuals with alpha 1-antitrypsin deficiency. Am J Respir Crit Care Med. 2003 Oct 1;168(7):818-900.

• 摘要

Sandhaus RA, Turino G, Brantly ML, et al. The diagnosis and management of alpha-1 antitrypsin deficiency in the adult. Chronic Obstr Pulm Dis (Miami). 2016;3:668-682.

• 全文

Marciniuk DD, Hernandez P, Balter M, et al. Alpha-1 antitrypsin deficiency targeted testing and augmentation therapy: a Canadian Thoracic Society clinical practice guideline. Can Respir J. 2012;19:109-116.

• 摘要

Chapman KR, Stockley RA, Dawkins C, et al. Augmentation therapy for alpha1 antitrypsin deficiency: a meta-analysis. COPD. 2009;6:177-184.

• 摘要

1.  Laurell CB, Eriksson S. The electrophoretic alpha 1-globulin pattern of serum in alpha 1-antitrypsin deficiency. Scand J Clin Lab Invest. 1963;15:132-140.

2.  Brantly M, Nukiwa T, Crystal RG. Molecular basis of alpha 1-antitrypsin deficiency. Am J Med. 1988;84:13-31.

• 摘要

3.  American Thoracic Society/European Respiratory Society Statement. Standards for the diagnosis and management of individuals with alpha 1-antitrypsin deficiency. Am J Respir Crit Care Med. 2003 Oct 1;168(7):818-900.

• 摘要

4.  Turino GM, Barker AF, Brantly ML, et al. Clinical features of individuals with PI*SZ phenotype of alpha-1 antitrypsin deficiency: alpha 1-antitrypsin deficiency registry study group. Am J Respir Crit Care Med. 1996;154:1718-1725.

• 摘要

5.  Wiedemann HP, Stoller JK. Lung disease due to alpha-1 antitrypsin deficiency. Curr Opin Pulm Med. 1996;2:155-160.

• 摘要

6.  Sveger T. Liver disease in alpha-1 antitrypsin deficiency detected by screening of 200,000 infants. N Engl J Med. 1976;294:1316-1321.

• 摘要

7.  Fregonese L, Stolk J. Hereditary alpha-1-antitrypsin deficiency and its clinical consequences. Orphanet J Rare Dis. 2008;3:16.

• 全文
• 摘要

8.  Lethbridge-Cejku M, Schiller JS, Bernadel L. Vital and Health Statistics, series 10, number 222: summary health statitiscs for US adults - National Health Interview Survey, 2002. Hyattsville, MD: National Center for Health Statistics; 2004.

• 全文

9.  Lieberman J, Winter B, Sastre A. Alpha 1-antitrypsin Pi-types in 965 COPD patients. Chest. 1986;89:370-373.

• 摘要

10.  Stoller JK, Aboussouan LS. Alpha 1-antitrypsin deficiency. Lancet. 2005;365:2225-2236.

• 摘要

11.  O'Brien ML, Buist NR, Murphey WH. Neonatal screening for alpha-1 antitrypsin deficiency. J Pediatr. 1978;92:1006-1010.

• 摘要

12.  Silverman EK, Miletich JP, Pierce JA, et al. Alpha-1 antitrypsin deficiency: high prevalence in the St. Louis area determined by direct population screening. Am Rev Respir Dis. 1989;140:961-966.

• 摘要

13.  Colp C, Pappas J, Moran D, et al. Variants of alpha-1 antitrypsin in Puerto Rican children with asthma. Chest. 1993;103:812-815.

• 摘要

14.  de Serres FJ, Blanco I, Fernandez-Bustillo E. Genetic epidemiology of alpha-1 antitrypsin deficiency in North America and Australia/New Zealand: Australia, Canada, New Zealand and the United States of America. Clin Genet. 2003;64:382-397.

• 摘要

15.  de Serres FJ. Worldwide racial and ethnic distribution of alpha-1 antitrypsin deficiency. Chest. 2002;122:1818-1829.

• 全文
• 摘要

16.  DeMeo DL, Silverman EK. Alpha1-antitrypsin deficiency. 2: genetic aspects of alpha-1 antitrypsin deficiency: phenotypes and genetic modifiers of emphysema risk. Thorax. 2004;59:259-264.

• 全文
• 摘要

17.  Kueppers F, Fallat R, Larson RK. Obstructive lung disease and alpha-1 antitrypsin deficiency gene heterozygosity. Science. 1969;165:899-901.

• 摘要

18.  Kueppers F, Black LF. Alpha-1 antitrypsin and its deficiency. Am Rev Respir Dis. 1974;110:176-194.

• 摘要

19.  Tobin MJ, Cook PJ, Hutchison DC. Alpha-1 antitrypsin deficiency: the clinical and physiological features of pulmonary emphysema in subjects homozygous for Pi-type-Z. A survey by the British Thoracic Association. Br J Dis Chest. 1983;77:14-27.

• 摘要

20.  Seersholm N, Kok-Jensen A, Dirksen A. Decline in FEV1 among patients with severe hereditary alpha-1 antitrypsin deficiency type Pi Z. Am J Respir Crit Care Med. 1995;152:1922-1925.

• 摘要

21.  Larsson C. Natural history and life expectancy in severe alpha 1-antitrypsin deficiency, Pi Z. Acta Med Scand. 1978;204:345-351.

• 摘要

22.  Alam S, Li Z, Atkinson C, et al. Z α1-antitrypsin confers a proinflammatory phenotype that contributes to chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2014;189:909-931.

• 摘要

23.  Molloy K, Hersh CP, Morris VB, et al. Clarification of the risk of chronic obstructive pulmonary disease in α1-antitrypsin deficiency PiMZ heterozygotes. Am J Respir Crit Care Med. 2014;189:419-427.

• 全文
• 摘要

24.  Kopito RR, Ron D. Conformational disease. Nat Cell Biol. 2000;2:E207-E209.

• 摘要

25.  Lomas DA, Mahadeva R. Alpha-1 antitrypsin polymerization and the serpinopathies: pathobiology and prospects for therapy. J Clin Invest. 2002;110:1585-1590.

• 摘要

26.  Mahadeva R, Shapiro SD. Chronic obstructive pulmonary disease 3: experimental animal models of pulmonary emphysema. Thorax. 2002;57:908-914.

• 全文
• 摘要

27.  Shapiro SD. Proteinases in chronic obstructive pulmonary disease. Biochem Soc Trans. 2002:30:98-102.

• 摘要

28.  Sandhaus RA, Turino G, Brantly ML, et al. The diagnosis and management of alpha-1 antitrypsin deficiency in the adult. Chronic Obstr Pulm Dis (Miami). 2016;3:668-682.

• 全文

29.  Stoller JK, Smith P, Yang P, et al. Physical and social impact of alpha-1 antitrypsin deficiency: results of a survey. Cleve Clin J Med. 1994;61:461-467.

• 摘要

30.  World Health Organization. Alpha-1 antitrypsin deficiency: memorandum from a WHO meeting. Bull World Health Organ. 1997;75:397-415.

• 摘要

31.  Eriksson S, Carlson J, Velez R. Risks for cirrhosis and primary liver cancer in alpha-1 antitrypsin deficiency. N Engl J Med. 1986;314:736-739.

• 摘要

32.  Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of COPD. December 2015. http://goldcopd.org (last accessed 26 September 2017).

• 全文

33.  Sorheim IC, Bakke P, Gulsvik A, et al. Alpha-1 antitrypsin protease inhibitor MZ heterozygosity is associated with airflow disruption in two large cohorts. Chest. 2010;138:1125-1132.

• 全文
• 摘要

34.  Marciniuk DD, Hernandez P, Balter M, et al. Alpha-1 antitrypsin deficiency targeted testing and augmentation therapy: a Canadian Thoracic Society clinical practice guideline. Can Respir J. 2012;19:109-116.

• 摘要

35.  Janus ED, Phillips NT, Carrell RW. Smoking, lung function, and alpha-1-antitrypsin deficiency. Lancet. 1985;1:152-154.

• 摘要

36.  Wu MC, Eriksson S. Lung function, smoking and survival in severe alpha 1-antitrypsin deficiency, PiZZ. J Clin Epidemiol. 1988;41:1157-1165.

• 摘要

37.  Piitulainen E, Eriksson S. Decline in FEV1 related to smoking status in individuals with severe alpha-1 antitrypsin deficiency (PiZZ). Eur Respir J. 1999;13:247-251.

• 全文
• 摘要

38.  Piitulainen E, Tornling G, Eriksson S. Effect of age and occupational exposure to airway irritants on lung function in non-smoking individuals with alpha-1 antitrypsin deficiency (PiZZ). Thorax. 1997;52:244-248.

• 全文
• 摘要

39.  Piitulainen E, Tornling G, Eriksson S. Environmental correlates of impaired lung function in non-smokers with severe alpha-1 antitrypsin deficiency (PiZZ). Thorax. 1998;53:939-943.

• 全文
• 摘要

40.  Silverman EK, Pierce JA, Province MA, et al. Variability of pulmonary function in alpha-1 antitrypsin deficiency: clinical correlates. Ann Intern Med. 1989;111:982-991.

• 摘要

41.  Piitulainen E, Sveger T. Effect of environmental and clinical factors on lung function and respiratory symptoms in adolescents with alpha-1 antitrypsin deficiency. Acta Paediatr. 1998;87:1120-1124.

• 摘要

42.  Clark VC, Dhanasekaran R, Brantly M, et al. Liver test results do not identify liver disease in adults with alpha-1 antitrypsin deficiency. Clin Gastroenterol Hepatol. 2012;10:1278-1283.

• 摘要

43.  McElvaney NG, Stoller JK, Buist AS, et al. Alpha-1 antitrypsin deficiency study group. Baseline characteristics of enrollees in the National Heart, Lung, and Blood Institute Registry of alpha-1 antitrypsin deficiency. Chest. 1997;111:394-403.

• 摘要

44.  Eden E, Mitchell D, Mehlman B, et al. Atopy, asthma and emphysema in patients with severe alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med. 1997 Jul;156(1):68-74.

• 摘要

45.  Lomas DA, Evans DL, Finch JT. The mechanism of Z alpha-1 antitrypsin accumulation in the liver. Nature. 1992;357:605-607.

• 摘要

46.  Ranes J, Stoller JK. A review of alpha-1 antitrypsin deficiency. Semin Respir Crit Care Med. 2005;26:154-166.

• 摘要

47.  Seersholm N, Kok-Jensen A, Dirksen A. Survival of patients with severe alpha-1 antitrypsin deficiency with special reference to non-index cases. Thorax. 1994;49:695-698.

• 全文
• 摘要

48.  Siri D, Farah H, Hogarth DK. Distinguishing alpha1-antitrypsin deficiency from asthma. Ann Allergy Asthma Immunol. 2013;111:458-464.

• 摘要

49.  American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Resp Crit Care Med. 1995;152(suppl):S77-S121.

• 摘要

50.  Alpha-1-Antitrypsin Deficiency Registry Study Group. Survival and FEV1 decline in individuals with severe deficiency of alpha 1-antitrypsin. Am J Respir Crit Care Med. 1998;158:49-59.

• 摘要

51.  Dirksen A, Dijkman JH, Madsen F, et al. A randomized clinical trial of alpha 1-antitrypsin augmentation therapy. Am J Respir Crit Care Med. 1999;160:1468-1472.

• 摘要

52.  Wencker M, Banik N, Buhl R, et al. Long-term treatment of alpha 1-antitrypsin deficiency-related pulmonary emphysema with human alpha 1-antitrypsin. Eur Respir J. 1998;11:428-433.

• 全文
• 摘要

53.  Seersholm N, Wencker M, Banik N, et al; Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL) alpha 1-AT study group. Does alpha 1-antitrypsin augmentation therapy slow the annual decline in FEV1 in patients with severe hereditary alpha 1-antitrypsin deficiency? Eur Respir J. 1997;10:2260-2263.

• 全文
• 摘要

54.  Gøtzsche PC, Johansen HK. Intravenous alpha-1 antitrypsin augmentation therapy for treating patients with alpha-1 antitrypsin deficiency and lung disease. Cochrane Database Syst Rev. 2010;(7):CD007851.

• 全文
• 摘要

55.  Stockley RA, Parr DG, Piitulainen E, et al. Therapeutic efficacy of alpha-1 antitrypsin augmentation therapy on the loss of lung tissue: an integrated analysis of 2 randomised clinical trials using computed tomography densitometry. Respir Res. 2010;11:136-143.

• 全文
• 摘要

56.  Chapman KR, Stockley RA, Dawkins C, et al. Augmentation therapy for alpha1 antitrypsin deficiency: a meta-analysis. COPD. 2009;6:177-184.

• 摘要

57.  Mohanka M, Khemasuwan D, Stoller JK. A review of augmentation therapy for alpha-1 antitrypsin deficiency. Expert Opin Biol Ther. 2012;12:685-700.

• 摘要

58.  National Institute of Health and Care Excellence. Management of chronic obstructive pulmonary disease in adults in primary and secondary care (partial update). June 2010. http://www.nice.org.uk (last accessed 26 September 2017).

• 全文

59.  Chapman KR, Burdon JG, Piitulainen E, et al; RAPID Trial Study Group. Intravenous augmentation treatment and lung density in severe α1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial. Lancet. 2015;386:360-368.

• 摘要

60.  Gadek JE, Klein HG, Holland PV, et al. Replacement therapy of alpha 1-antitrypsin deficiency: reversal of protease-antiprotease imbalance within the alveolar structures of PiZ subjects. J Clin Invest. 1981;68:1158-1165.

• 全文
• 摘要

61.  Wewers MD, Casolaro MA, Sellers SE, et al. Replacement therapy for alpha 1-antitrypsin deficiency associated with emphysema. N Engl J Med. 1987;316:1055-1062.

• 摘要

62.  Barker AF, Iwata-Morgan I, Oveson L, et al. Pharmacokinetic study of alpha 1-antitrypsin infusion in alpha 1-antitrypsin deficiency. Chest. 1997;112:607-613.

• 摘要

63.  Hubbard RC, Sellers S, Czerski D, et al. Biochemical efficacy and safety of monthly augmentation therapy for alpha 1-antitrypsin deficiency. JAMA. 1988;260:1259-1264.

• 摘要

64.  Stoller JK, Fallat R, Schluchter MD, et al. Augmentation therapy with alpha-1 antitrypsin: patterns of use and adverse events. Chest. 2003;123:1425-1434.

• 全文
• 摘要

65.  Stoller JK, Rouhani F, Brantly M, et al. Biochemical efficacy and safety of a new pooled human plasma alpha 1-antitrypsin, Respitin. Chest. 2002;122:66-74.

• 全文
• 摘要

66.  Gildea TR, Shermock KM, Singer ME, et al. Cost-effectiveness analysis of augmentation therapy for severe alpha1-antitrypsin deficiency. Am J Respir Crit Care Med. 2003;167:1387-1392.

• 摘要

67.  Barros-Tizon JC, Torres ML, Blanco I, et al; Investigators of the rEXA Study Group. Reduction of severe exacerbations and hospitalization-derived costs in alpha-1-antitrypsin-deficient patients treated with alpha-1-antitrypsin augmentation therapy. Ther Adv Respir Dis. 2012;6:67-78.

• 摘要

68.  Hosenpud JD, Novick RJ, Breen TJ, et al. The registry of the International Society for Heart and Lung Transplanation: twelfth official report. J Heart Lung Transplant. 1995;14:805-815.

• 摘要

69.  Levine SM, Anzueto A, Peters JI, et al. Medium term functional results of single-lung transplantation for end stage obstructive lung disease. Am J Respir Crit Care Med. 1994;150:398-402.

• 摘要

70.  Christie JD, Edwards LB, Kucheryavaya AY, et al. The registry of the International Society for Heart and Lung Transplantation: twenty-eighth adult lung and heart-lung transplant report - 2011. J Heart Lung Transplant. 2011;30:1104-1122.

• 全文
• 摘要

71.  Carey EJ, Iyer VN, Nelson DR, et al. Outcomes for recipients of liver transplantation for alpha-1-antitrypsin deficiency–related cirrhosis. Liver Transpl. 2013;19:1370-1376.

• 摘要

72.  Hubbard RC, Crystal RG. Strategies for aerosol therapy of alpha 1-antitrypsin deficiency by the aerosol route. Lung. 1990;168 (Suppl):565-578.

• 摘要

73.  Stolk J, Camps J, Feitsma HI, et al. Pulmonary deposition and disappearance of aerosolised secretory leucocyte protease inhibitor. Thorax. 1995;50:645-650.

• 摘要

74.  Gorin AB, Stewart PA. Differential permeability of endothelial and epithelial barriers to albumin flux. J Appl Physiol. 1979;47:1315-1324.

• 摘要

75.  Llewellyn-Jones CG, Lomas DA, Stockley RA. Potential role of recombinant secretory leucoprotease inhibitor in the prevention of neutrophil mediated matrix degradation. Thorax. 1994;49:567-572.

• 摘要

76.  Kolodka TM, Finehold M, Woo SL. Hepatic gene therapy: efficient retroviral-mediated gene transfer into rat hepatocytes in vivo. Somat Cell Mol Genet. 1993;19:491-497.

• 摘要

77.  Song S, Morgan M, Ellis T, et al. Sustained secretion of human alpha-1 antitrypsin from murine muscle transduced with adeno-associated virus vectors. Proc Natl Acad Sci USA. 1998;95:14384-14388.

• 全文
• 摘要

78.  Stoller JK, Gildea TR, Ries AL, et al. Lung volume reduction surgery in patients with emphysema and alpha-1 antitrypsin deficiency. Ann Thoracic Surg. 2007;83:241-251.

• 摘要

79.  ClinicalTrials.gov. Evaluation of the Spiration Valve System for emphysema to improve lung function (EMPROVE). May 2016. https://clinicaltrials.gov (last accessed 26 September 2017).

• 全文

80.  Stolk J, Stockley RA, Stoel BC, et al. Randomised controlled trial for emphysema with a selective agonist of the γ-type retinoic acid receptor. Eur Respir J. 2012;40:306-312.

• 摘要

81.  Moreno JA, Ortega-Gomez A, Rubio-Navarro A, et al. High density lipoproteins potentiate alpha-1 antitrypsin therapy in elastase-induced pulmonary emphysema. Am J Respir Cell Mol Biol. 2014;51:536-549.

• 摘要

82.  Dawkins PA, Dowson LJ, Guest PJ, et al. Predictors of mortality in alpha 1-antitrypsin deficiency. Thorax. 2003;58:1020-1026.

• 全文
• 摘要

83.  Seersholm N, Dirksen A, Kok-Jensen A. Airways obstruction and two-year survival in patients with severe alpha-1 antitrypsin deficiency. Eur Respir J. 1994;7:1985-1987.

• 摘要

84.  Eriksson S. Alpha 1-antitrypsin deficiency: natural course and therapeutic strategies. In: Boyer J, Blum HE, Maier KP, et al, eds. Cirrhosis and its development. Falk Symposium 115. Dordrecht, Netherlands: Kluwer Academic; 2000:307-315.

85.  Bruix J, Sherman M; Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology. 2005 Nov;42(5):1208-36.

• 全文
• 摘要

86.  World Health Organization. Alpha1-antitrypsin deficiency: memorandum from a WHO meeting. Bull World Health Organ. 1997;75:397-415.

87.  Elzouki AN, Segelmark M, Wieslander J, et al. Strong link between the alpha1-antitrypsin PiZ allele and Wegener's granulomatosis. J Intern Med. 1994 Nov;236(5):543-8.

• 摘要

88.  Lhotta K, Vogel W, Meisl T, et al. Alpha1-antitrypsin phenotypes in patients with anti-neutrophil cytoplasmic antibody-positive vasculitis. Clin Sci (Lond). 1994 Dec;87(6):693-5.

• 摘要

89.  Segelmark M, Elzouki AN, Wieslander J, et al. The PiZ gene of alpha1-antitrypsin as a determinant of outcome in PR3-ANCA-positive vasculitis. Kidney Int. 1995 Sep;48(3):844-50.

• 摘要